Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.

Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M.

Neuro Oncol. 2016 Sep;18(9):1242-52. doi: 10.1093/neuonc/now043. Epub 2016 Mar 23.

2.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

3.

Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.

Oude Munnink TH, Tamas KR, Lub-de Hooge MN, Vedelaar SR, Timmer-Bosscha H, Walenkamp AM, Weidner KM, Herting F, Tessier J, de Vries EG.

J Nucl Med. 2013 Jun;54(6):929-35. doi: 10.2967/jnumed.112.112086. Epub 2013 Apr 26.

4.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

5.

A PDZ domain protein interacts with the C-terminal tail of the insulin-like growth factor-1 receptor but not with the insulin receptor.

Ligensa T, Krauss S, Demuth D, Schumacher R, Camonis J, Jaques G, Weidner KM.

J Biol Chem. 2001 Sep 7;276(36):33419-27. Epub 2001 Jul 9.

6.

Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1.

Keilhack H, Müller M, Böhmer SA, Frank C, Weidner KM, Birchmeier W, Ligensa T, Berndt A, Kosmehl H, Günther B, Müller T, Birchmeier C, Böhmer FD.

J Cell Biol. 2001 Jan 22;152(2):325-34.

7.

Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis.

Stefan M, Koch A, Mancini A, Mohr A, Weidner KM, Niemann H, Tamura T.

J Biol Chem. 2001 Feb 2;276(5):3017-23. Epub 2000 Nov 7.

8.

Functional cloning of ARM-1, an adhesion-regulating molecule upregulated in metastatic tumor cells.

Simins AB, Weighardt H, Weidner KM, Weidle UH, Holzmann B.

Clin Exp Metastasis. 1999;17(8):641-8.

PMID:
10919708
9.

Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family.

Vayssière B, Zalcman G, Mahé Y, Mirey G, Ligensa T, Weidner KM, Chardin P, Camonis J.

FEBS Lett. 2000 Feb 4;467(1):91-6.

10.

FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation.

Tamura T, Mancini A, Joos H, Koch A, Hakim C, Dumanski J, Weidner KM, Niemann H.

Oncogene. 1999 Nov 11;18(47):6488-95.

11.

The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Tulasne D, Paumelle R, Weidner KM, Vandenbunder B, Fafeur V.

Mol Biol Cell. 1999 Mar;10(3):551-65.

12.

The SH2-containing adapter protein GRB10 interacts with BCR-ABL.

Bai RY, Jahn T, Schrem S, Munzert G, Weidner KM, Wang JY, Duyster J.

Oncogene. 1998 Aug 27;17(8):941-8.

13.

Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.

Jeffers M, Taylor GA, Weidner KM, Omura S, Vande Woude GF.

Mol Cell Biol. 1997 Feb;17(2):799-808.

14.

Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis.

Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W.

Nature. 1996 Nov 14;384(6605):173-6.

PMID:
8906793
15.

Motogenic and morphogenic activity of epithelial receptor tyrosine kinases.

Sachs M, Weidner KM, Brinkmann V, Walther I, Obermeier A, Ullrich A, Birchmeier W.

J Cell Biol. 1996 Jun;133(5):1095-1107.

16.

Interaction between the phosphotyrosine binding domain of Shc and the insulin receptor is required for Shc phosphorylation by insulin in vivo.

Isakoff SJ, Yu YP, Su YC, Blaikie P, Yajnik V, Rose E, Weidner KM, Sachs M, Margolis B, Skolnik EY.

J Biol Chem. 1996 Feb 23;271(8):3959-62.

17.

Epithelial differentiation and the control of metastasis in carcinomas.

Birchmeier W, Behrens J, Weidner KM, Hülsken J, Birchmeier C.

Curr Top Microbiol Immunol. 1996;213 ( Pt 2):117-35. Review. No abstract available.

PMID:
9053287
18.

Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells.

Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W.

J Cell Biol. 1995 Dec;131(6 Pt 1):1573-86.

19.

Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland.

Yang Y, Spitzer E, Meyer D, Sachs M, Niemann C, Hartmann G, Weidner KM, Birchmeier C, Birchmeier W.

J Cell Biol. 1995 Oct;131(1):215-26.

20.

Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.

Weidner KM, Sachs M, Riethmacher D, Birchmeier W.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2597-601.

21.
23.

Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas.

Birchmeier W, Weidner KM, Hülsken J, Behrens J.

Semin Cancer Biol. 1993 Aug;4(4):231-9. Review.

PMID:
8400145
24.

Elicitation of distinct populations of monoclonal antibodies specific for the variable domains of monoclonal anti-fluorescein antibody 4-4-20.

Weidner KM, Denzin LK, Kim ML, Mallender WD, Miklasz SD, Voss EW Jr.

Mol Immunol. 1993 Aug;30(11):1003-11.

PMID:
8350870
26.

Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development.

Birchmeier C, Sonnenberg E, Weidner KM, Walter B.

Bioessays. 1993 Mar;15(3):185-90. Review.

PMID:
8387784
27.

Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met.

Weidner KM, Hartmann G, Sachs M, Birchmeier W.

Am J Respir Cell Mol Biol. 1993 Mar;8(3):229-37. Review.

PMID:
8383506
28.

Expression of the met-receptor and its ligand, HGF-SF during mouse embryogenesis.

Sonnenberg E, Weidner KM, Birchmeier C.

EXS. 1993;65:381-94. Review.

PMID:
8380744
29.

Molecular characteristics of HGF-SF and its role in cell motility and invasion.

Weidner KM, Hartmann G, Naldini L, Comoglio PM, Sachs M, Fonatsch C, Rieder H, Birchmeier W.

EXS. 1993;65:311-28. Review.

PMID:
8380739
30.

Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells.

Birchmeier W, Weidner KM, Behrens J.

J Cell Sci Suppl. 1993;17:159-64. Review.

PMID:
8144693
31.

Comparative circular dichroism studies of an anti-fluorescein monoclonal antibody (Mab 4-4-20) and its derivatives.

Tetin SYu, Mantulin WW, Denzin LK, Weidner KM, Voss EW Jr.

Biochemistry. 1992 Dec 8;31(48):12029-34.

PMID:
1457402
32.

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.

Hartmann G, Naldini L, Weidner KM, Sachs M, Vigna E, Comoglio PM, Birchmeier W.

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11574-8.

33.

Molecular stabilization effects of interactions between anti-metatype antibodies and liganded antibody.

Weidner KM, Denzin LK, Voss EW Jr.

J Biol Chem. 1992 May 25;267(15):10281-8.

34.

Characterization of interactions involving anti-metatype antibodies and immune complexes.

Weidner KM, Voss EW Jr.

Mol Immunol. 1992 Mar;29(3):303-12.

PMID:
1372954
35.

Importance of dynamic properties of idiotopes in interactions with anti-Id antibodies.

Voss EW Jr, Weidner KM, Denzin LK.

Immunol Invest. 1992 Feb;21(1):71-83. Review.

PMID:
1548048
36.

Dominant and recessive genes involved in tumor cell invasion.

Birchmeier W, Behrens J, Weidner KM, Frixen UH, Schipper J.

Curr Opin Cell Biol. 1991 Oct;3(5):832-40. Review.

PMID:
1931083
37.

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al.

EMBO J. 1991 Oct;10(10):2867-78.

38.

Evidence for the identity of human scatter factor and human hepatocyte growth factor.

Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikuhara Y, et al.

Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7001-5.

39.

Immunological characterization of xenogenic anti-metatype antibodies.

Weidner KM, Voss EW Jr.

J Biol Chem. 1991 Feb 5;266(4):2513-9.

40.

The role of E-cadherin and scatter factor in tumor invasion and cell motility.

Behrens J, Weidner KM, Frixen UH, Schipper JH, Sachs M, Arakaki N, Daikuhara Y, Birchmeier W.

EXS. 1991;59:109-26. Review.

PMID:
1833225
41.

Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells.

Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W.

J Cell Biol. 1990 Nov;111(5 Pt 1):2097-108.

42.

Immunological and structural characterization of a high affinity anti-fluorescein single-chain antibody.

Bedzyk WD, Weidner KM, Denzin LK, Johnson LS, Hardman KD, Pantoliano MW, Asel ED, Voss EW Jr.

J Biol Chem. 1990 Oct 25;265(30):18615-20.

Supplemental Content

Loading ...
Support Center